Opatanol

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
24-08-2022
产品特点 产品特点 (SPC)
24-08-2022
公众评估报告 公众评估报告 (PAR)
10-12-2013

有效成分:

olopatadine hydrochloride

可用日期:

Novartis Europharm Limited

ATC代码:

S01GX09

INN(国际名称):

olopatadine

治疗组:

Ophthalmologicals

治疗领域:

Conjunctivitis, Allergic

疗效迹象:

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.,

產品總結:

Revision: 23

授权状态:

Authorised

授权日期:

2002-05-16

资料单张

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET: INFORMATION FOR THE USER
OPATANOL 1 MG/ML EYE DROPS, SOLUTION
olopatadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Opatanol is and what it is used for
2.
What you need to know before you use Opatanol
3.
How to use Opatanol
4.
Possible side effects
5.
How to store Opatanol
6.
Contents of the pack and other information
1.
WHAT OPATANOL IS AND WHAT IT IS USED FOR
OPATANOL IS USED FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF SEASONAL
ALLERGIC CONJUNCTIVITIS.
ALLERGIC CONJUNCTIVITIS.
Some materials (allergens) like pollens, house dust or animal fur may
cause
allergic reactions resulting in itching, redness as well as swelling
of the surface of your eye.
OPATANOL IS A MEDICINE
for treatment of allergic conditions of the eye. It works by reducing
the
intensity of the allergic reaction.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OPATANOL
DO NOT USE OPATANOL
•
IF YOU ARE ALLERGIC
(hypersensitive) to olopatadine or any of the other ingredients of
this
medicine (listed in section 6).
•
You should not use Opatanol if you are breast-feeding.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before using Opatanol.
You should remove contact lenses that are in your eyes before using
Opatanol.
CHILDREN
Do not use Opatanol in children under the age of 3 years. Do not give
this
medicine to children under
the ages of 3 years because there is no data to indicate that it is
safe and work in children under
3 years.
OTHER MEDICINES AND OPATANOL
Tell your doctor or
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Opatanol 1 mg/mL eye drops, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One mL of solution contains 1 mg olopatadine (as hydrochloride).
Excipient(s) with known effect
Benzalkonium chloride 0.1 mg/ml.
Disodium phosphate dodecahydrate (E339) 12.61 mg/ml (equivalent to
3.34 mg/ml of phosphates).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Eye drops, solution (eye drops).
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of ocular signs and symptoms of seasonal allergic
conjunctivitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dose is one drop of Opatanol in the conjunctival sac of the
affected eye(s) twice daily (8 hourly).
Treatment may be maintained for up to four months, if considered
necessary.
_Use in elderly _
No dosage adjustment in elderly patients is necessary.
_Paediatric patients _
Opatanol may be used in paediatric patients three years of age and
older at the same dose as in adults.
The safety and efficacy of Opatanol in children aged under 3 years has
not been established. No data
are available.
_Use in hepatic and renal impairment _
Olopatadine in the form of eye drops (Opatanol) has not been studied
in patients with renal or hepatic
disease. However, no dosage adjustment is expected to be necessary in
hepatic or renal impairment
(see section 5.2).
3
Method of administration
For ocular use only.
After the bottle cap is removed, if the tamper evident snap collar is
loose, remove before using the
product. To prevent contamination of the dropper tip and solution,
care must be taken not to touch the
eyelids, surrounding areas, or other surfaces with the dropper tip of
the bottle. Keep the bottle tightly
closed when not in use.
In case of concomitant therapy with other topical ocular medicines, an
interval of five minutes should
be allowed between successive applications. Eye ointments should be
administered last.
4.3
CONTRAINDICATIONS
Hy
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 24-08-2022
产品特点 产品特点 保加利亚文 24-08-2022
公众评估报告 公众评估报告 保加利亚文 10-12-2013
资料单张 资料单张 西班牙文 24-08-2022
产品特点 产品特点 西班牙文 24-08-2022
公众评估报告 公众评估报告 西班牙文 10-12-2013
资料单张 资料单张 捷克文 24-08-2022
产品特点 产品特点 捷克文 24-08-2022
公众评估报告 公众评估报告 捷克文 10-12-2013
资料单张 资料单张 丹麦文 24-08-2022
产品特点 产品特点 丹麦文 24-08-2022
公众评估报告 公众评估报告 丹麦文 10-12-2013
资料单张 资料单张 德文 24-08-2022
产品特点 产品特点 德文 24-08-2022
公众评估报告 公众评估报告 德文 10-12-2013
资料单张 资料单张 爱沙尼亚文 24-08-2022
产品特点 产品特点 爱沙尼亚文 24-08-2022
公众评估报告 公众评估报告 爱沙尼亚文 10-12-2013
资料单张 资料单张 希腊文 24-08-2022
产品特点 产品特点 希腊文 24-08-2022
公众评估报告 公众评估报告 希腊文 10-12-2013
资料单张 资料单张 法文 24-08-2022
产品特点 产品特点 法文 24-08-2022
公众评估报告 公众评估报告 法文 10-12-2013
资料单张 资料单张 意大利文 24-08-2022
产品特点 产品特点 意大利文 24-08-2022
公众评估报告 公众评估报告 意大利文 10-12-2013
资料单张 资料单张 拉脱维亚文 24-08-2022
产品特点 产品特点 拉脱维亚文 24-08-2022
公众评估报告 公众评估报告 拉脱维亚文 10-12-2013
资料单张 资料单张 立陶宛文 24-08-2022
产品特点 产品特点 立陶宛文 24-08-2022
公众评估报告 公众评估报告 立陶宛文 10-12-2013
资料单张 资料单张 匈牙利文 24-08-2022
产品特点 产品特点 匈牙利文 24-08-2022
公众评估报告 公众评估报告 匈牙利文 10-12-2013
资料单张 资料单张 马耳他文 24-08-2022
产品特点 产品特点 马耳他文 24-08-2022
公众评估报告 公众评估报告 马耳他文 10-12-2013
资料单张 资料单张 荷兰文 24-08-2022
产品特点 产品特点 荷兰文 24-08-2022
公众评估报告 公众评估报告 荷兰文 10-12-2013
资料单张 资料单张 波兰文 24-08-2022
产品特点 产品特点 波兰文 24-08-2022
公众评估报告 公众评估报告 波兰文 10-12-2013
资料单张 资料单张 葡萄牙文 24-08-2022
产品特点 产品特点 葡萄牙文 24-08-2022
公众评估报告 公众评估报告 葡萄牙文 10-12-2013
资料单张 资料单张 罗马尼亚文 24-08-2022
产品特点 产品特点 罗马尼亚文 24-08-2022
公众评估报告 公众评估报告 罗马尼亚文 10-12-2013
资料单张 资料单张 斯洛伐克文 24-08-2022
产品特点 产品特点 斯洛伐克文 24-08-2022
公众评估报告 公众评估报告 斯洛伐克文 10-12-2013
资料单张 资料单张 斯洛文尼亚文 24-08-2022
产品特点 产品特点 斯洛文尼亚文 24-08-2022
公众评估报告 公众评估报告 斯洛文尼亚文 10-12-2013
资料单张 资料单张 芬兰文 24-08-2022
产品特点 产品特点 芬兰文 24-08-2022
公众评估报告 公众评估报告 芬兰文 10-12-2013
资料单张 资料单张 瑞典文 24-08-2022
产品特点 产品特点 瑞典文 24-08-2022
公众评估报告 公众评估报告 瑞典文 10-12-2013
资料单张 资料单张 挪威文 24-08-2022
产品特点 产品特点 挪威文 24-08-2022
资料单张 资料单张 冰岛文 24-08-2022
产品特点 产品特点 冰岛文 24-08-2022
资料单张 资料单张 克罗地亚文 24-08-2022
产品特点 产品特点 克罗地亚文 24-08-2022
公众评估报告 公众评估报告 克罗地亚文 10-12-2013

搜索与此产品相关的警报

查看文件历史